Proguanylin (guanylate cyclase activator 2A, guanylate cyclase-activating protein 1), is a precursor to the hormone guanylin, and plays a significant role in various physiological processes in the kidney and intestine through activation of guanylate cyclase C receptor.1 In Crohn’s disease, serum proguanylin levels are notably reduced compared to healthy individuals, and levels increase following anti-inflammatory treatment, suggesting its potential as a biomarker for disease activity and therapeutic response.2-4 In the context of hypertension, elevated proguanylin levels have been observed in individuals with high blood pressure, indicating a possible role in sodium metabolism and blood pressure regulation.5
Enzyme Immunoassay for the quantitative determination of Proguanylin in human serum and plasma.
REFERENCES
- Mueller T, Dieplinger B. The guanylin peptide family and the proposed gastrointestinal-renal natriuretic signaling axis. Kidney Int. 2012 Dec;82(12):1253-5.
- Pitari GM. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Drug Des Devel Ther. 2013 Apr 19;7:351-60.
- Dye FS etal. Characterisation of proguanylin expressing cells in the intestine – evidence for constitutive luminal secretion. Sci Rep. 2019 Oct 30;9(1):15574.
- Kałużna A, Jura-Półtorak A, Derkacz A, Jaruszowiec J, Olczyk K, Komosinska-Vassev K. Circulating Profiles of Serum Proguanylin, S100A12 Protein and Pentraxin 3 as Diagnostic Markers of Ulcerative Colitis. J Clin Med. 2023 Jun 28;12(13):4339.
- von Volkmann HL, Brønstad I, Tronstad RR, Dizdar V, Nylund K, Hanevik K, Hausken T, Gilja OH, Fiskerstrand T. Plasma levels of guanylins are reduced in patients with Crohn’s disease. Scand J Gastroenterol. 2020 Apr;55(4):449-453.
